Items where authors include "Fonarow, G.C."
Article
Nakao, Y.M, Nakao, K., Nadarajah, R. et al. (6 more authors) (2023) Prognosis, characteristics, and provision of care for patients with the unspecified heart failure electronic health record phenotype: a population-based linked cohort study of 95262 individuals. EClinicalMedicine, 63. 102164. ISSN 2589-5370
Landmesser, U., Lindgren, P., Hagström, E. et al. (7 more authors) (2022) Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal - Quality of Care and Clinical Outcomes, 8 (1). pp. 31-38. ISSN 2058-5225
Fonarow, G.C., van Hout, B. orcid.org/0000-0001-9698-6094, Villa, G. et al. (2 more authors) (2019) Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiology, 4 (7). pp. 691-695. ISSN 2380-6583
Fonarow, G.C., Keech, A.C., Pedersen, T.R. et al. (8 more authors) (2017) Cost-effectiveness of Evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiology, 2 (10). pp. 1069-1078. ISSN 2380-6583
Villa, G., Lothgren, M., Kutikova, L. et al. (7 more authors) (2017) Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics, 39 (4). pp. 771-786. ISSN 0149-2918
Gandra, S.R., Villa, G., Fonarow, G.C. et al. (4 more authors) (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39 (6). pp. 313-320. ISSN 0160-9289